A well known Ayurvedic formulation Ashokarista, used for menstrual disorders has beenstudied in a single blind randomised placebo controlled clinical trial for the treatment ofmenorrhagia and dysmenorrhoea. Dysmenorrhoea and menorrhagia patients who were takingAshokarista (20 ml twice daily) for 10 menstrual cycles had an increase in haemoglobin level.Menorrhagia treated group has shown to reduce the erythrocyte sedimentation rate level that hasbeen increased in the menorrhagia control group. The platelet count, total count and differentialcount were observed unchanged in the study. The Ashokarista did not affect the SGPT and SGOTlevel, which signify its lack of toxicity in hepatic function. The treated menorrhagic patientsshowed an increase in serum albumin content and decrease in blood clotting time, whereas theserum protein content was observed unchanged. There was a significant increase in both serumcholesterol and triglyceride level, which usually associated with the use of oral contraceptives. Nomajor side effects were observed by the clinicians during the study.